



FINANCIAL SNAPSHOT

NASDAQ/TSX:	AEZS
SHARE PRICE:*	\$ 1.35
MARKET CAP:*	~\$162M
SHARES OUTSTANDING:	~120M

*As of March 17, 2021

Investor and
Media Relations
JTC Team
833.475.8247
aezs@jtcir.com

Specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests

Where We Are Today

Investment Highlights



Macimorelin

First and only approved oral drug indicated for diagnosis of adult growth hormone deficiency (AGHD)



United States and Canada Commercial and Development Partner

Novo Nordisk is the global leader in growth hormone deficiency therapeutic market



European Commercial Partner

Consilient Health is a privately owned pharma company focused on commercializing medicines in Europe and the Middle East

Growth Opportunities

Childhood-Onset Growth Hormone Deficiency (CGHD) Testing



Leveraging AGHD Approval and Compelling Safety Profile¹

Macimorelin as a Therapeutic



Working with
The University of Queensland













Pipeline Expansion



Advancing Therapeutic and Vaccine Programs

1: Macrilen [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; 2018; Macimorelin summary of product characteristics (SmPC) approved by European Commission

Commercial and Development Pipeline

		Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Commercial	Commercial Rights				
									U.S./Canada	Europe	Israel	ROW	
Diagnostics	Macimorelin	Adult Growth Hormone Deficiency (AGHD)											
	Macimorelin	Childhood-Onset Growth Hormone Deficiency (CGHD)											
Program Highlights													
Therapeutics	AIM Biologicals	Neuromyelitis Optica Spectrum Disorder (NMOSD)							In-licensed program in January 2021				
	Macimorelin	Undisclosed Neurodegenerative Disease							Entered material transfer agreement and option to in-license in January 2021				
	Delayed Clearance Parathyroid Hormone (DC-PTH) Fusion Polypeptides	Primary Hypoparathyroidism							In-licensed program in March 2021				
Program Highlights													
Vaccine	Oral Coronavirus Vaccine Platform	Covid-19 (SARS-CoV-2)							In-licensed program in March 2021				

Macimorelin Commercial Rights

Actively seeking commercial partners in ROW

License and Assignment Agreement

- Territories: United States and Canada
- Royalties on sales
- Sales milestones
- Aeterna Zentaris controls API supply chain and provides API
- Co-development for expansion into CGHD
 - Novo Nordisk to fund 100% of budgeted Study P02 trial expenses up to €9 million
 - Potential additional expenses to be shared



Consilient Health License Agreement

- Territories: Europe and the United Kingdom
- Pricing and reimbursement milestones
- Royalties on sales
- Aeterna Zentaris controls supply chain and provides finished product according to supply agreement

AETERNA ZENTARIS

Owens Worldwide Rights Outside of U.S., Canada, Europe, Israel and Palestine Authority

Distribution and Commercialization Agreement in Israel and the Palestine Authority



Leveraging Clinical Success and Compelling Safety Profile

Expand Macimorelin Into CGHD Testing Through Use of Pediatric Development Plan

CGHD Clinical Development Strategy

Dose Finding Study (P01)

Positive results announced April 2020



- Co-Development with Novo Nordisk (NN)
- Aeterna Zentaris to be the responsible Sponsor overseeing the study
- NN to fund 100% of budgeted Study P02 trial expenses up to €9 million
- Potential additional expenses to be shared

Provides Framework for Study P02

Pivotal Study (P02): Test Efficacy and Safety

Expected commencement date


Early Q2 2021

Expected Value Driving Milestones

- ✓ Successful completion of Study P01
- ✓ Amended agreement with Novo Nordisk
- ✓ European Licensing Agreement with Consilient Health Ltd.

Planned start of CGHD clinical safety and efficacy study (AEZS-130-P02 - multi-national, including U.S.)

Planned submission - FDA and EMA CGHD dossiers



Potential upside by additional pipeline activities